Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
出版年份 2022 全文链接
标题
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
作者
关键词
-
出版物
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2022-06-01
DOI
10.1093/neuonc/noac139
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IDH1 Non-Canonical Mutations and Survival in Patients with Glioma
- (2021) Enrico Franceschi et al. Diagnostics
- Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
- (2021) C. Mircea S. Tesileanu et al. ACTA NEUROPATHOLOGICA
- Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
- (2021) Ingo K. Mellinghoff et al. CLINICAL CANCER RESEARCH
- Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia
- (2021) Jorge E. Cortes et al. BLOOD
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
- (2020) Jorge E. Cortes et al. BLOOD
- Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
- (2020) Justin M. Watts et al. BLOOD
- Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor
- (2020) Justin A. Caravella et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
- (2020) Ingo K. Mellinghoff et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
- (2019) Jiayi Huang et al. JOURNAL OF NEURO-ONCOLOGY
- Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients
- (2019) Christina K. Cramer et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- 2-Hydroxyglutarate in Cancer Cells
- (2019) Petr Ježek ANTIOXIDANTS & REDOX SIGNALING
- Wild-type and mutated IDH1/2 enzymes and therapy responses
- (2018) Remco J. Molenaar et al. ONCOGENE
- Current Challenges and Opportunities in Treating Glioblastoma
- (2018) Andrea Shergalis et al. PHARMACOLOGICAL REVIEWS
- Mutant IDH1 Promotes Glioma Formation In Vivo
- (2018) Beatrice Philip et al. Cell Reports
- A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- (2018) Justin M. Watts et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary brain tumours in adults
- (2018) Sarah Lapointe et al. LANCET
- IDH1: Linking Metabolism and Epigenetics
- (2018) Silvia Raineri et al. Frontiers in Genetics
- Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
- (2017) Benjamin M. Ellingson et al. Neurotherapeutics
- NADPH: new oxygen for the ROS theory of aging
- (2016) Pablo J. Fernandez-Marcos et al. Oncotarget
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- IDH1 and IDH2 Mutations in Gliomas
- (2013) Adam L. Cohen et al. Current Neurology and Neuroscience Reports
- The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
- (2013) Dinesh Rakheja et al. Frontiers in Oncology
- The efficacy of temozolomide for recurrent glioblastoma multiforme
- (2012) Chao Chen et al. EUROPEAN JOURNAL OF NEUROLOGY
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- IDH1 mutation of gliomas with long-term survival analysis
- (2012) JAE KYUNG MYUNG et al. ONCOLOGY REPORTS
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
- (2011) MJ van den Bent et al. LANCET ONCOLOGY
- Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism
- (2010) Z. J. Reitman et al. JNCI-Journal of the National Cancer Institute
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now